Atossa Therapeutics, Inc. (ATOS) vs Kyntra Bio, Inc. (KYNB)
A side-by-side comparison of Atossa Therapeutics, Inc. and Kyntra Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ATOS
Atossa Therapeutics, Inc.
$2.53HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
KYNB
Kyntra Bio, Inc.
$6.10HealthcareDelayed quote: Oct 6, 2026, 10:01 AM EDT
Total return — ATOS vs KYNB
growth of $100 · dividends reinvested · last 10yATOS -99.3% (-39.4%/yr)KYNB -98.8% (-35.8%/yr)KYNB compounded faster over this window
ATOS KYNB
ATOS vs KYNB: by the numbers
- •ATOS is the larger company ($25M vs $25M market cap).
- •KYNB is profitable (3967.77% net margin) while ATOS runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | ATOS | KYNB |
|---|---|---|
| P/S ratio | N/A | 5.35 |
| P/B ratio | 0.94 | N/A |
Profitability
| Metric | ATOS | KYNB |
|---|---|---|
| Gross margin | 0.00% | 91.37% |
| Operating margin | 0.00% | -712.66% |
| Net margin | 0.00% | 3967.77% |
| ROE | -140.55% | N/A |
| ROIC | -146.30% | -78.16% |
Growth (annualized)
| Metric | ATOS | KYNB |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -51.49% |
| Total return CAGR (5Y) | -44.50% | -52.67% |
Frequently asked
- Is ATOS or KYNB more profitable?
- KYNB runs the higher net margin — ATOS at 0.00% versus KYNB at 3967.77%.
- How have ATOS and KYNB total returns compared?
- Over the past 10 years, ATOS delivered -39.47% and KYNB delivered -35.88% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.